We develop a portfolio of long-acting injection products in various therapeutic areas by combining our BEPO® proprietary technology with existing and already-marketed active pharmaceutical ingredients.
Our most advanced products, which address the treatment of schizophrenia and postoperative orthopedic pain, are respectively in a Phase 3 and Phase 2 clinical trial in the United States.
Latest news
Read full story
The analysts listed above follow MedinCell. Any opinions, estimates or forecasts regarding MedinCell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of MedinCell or its management. MedinCell does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analysts and institutions.
General Meeting
Thursday, 10 September 2020
Half-year liquidity contract statement - 07.08.2020
Half-Year liquidity contract report (in French) - 01.09.2020
Half year report (French) - 12.03.2019
Transcript (French)
Replay • Video Conference (French)
Presentation (French)
Corporate presentation - January 2020
Corporate presentation - September 2019
JP Morgan 2019 Presentation - Jan. 2019
MedinCell David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier / Alexia Faure
medincell@newcap.eu
+33 (0)1 44 71 94 94
NewCap Nicolas Merigeau